Navigation Links
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Date:5/13/2008

DELAND, Fla., May 13 /PRNewswire/ -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy.

Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, "It is my pleasure to serve as the medical monitor for the prostate cancer clinical trial program evaluating the safety and effectiveness of the Sonablate(R) 500 HIFU device."

"I have personally reviewed the preliminary data and observed the Sonablate(R) 500 in action and I am impressed with this advanced technology for ablating the prostate. These rigorous clinical trials will help define the appropriate role of the Sonablate(R) 500 device in the treatment of prostate cancer," Lepor added.

This trial will be conducted at various sites across the U.S. and is expected to enroll approximately 202 subjects and 10 clinical centers. This clinical trial is based on results from the feasibility trial completed in October 2007 which enrolled 11 subjects from two clinical research sites within the U.S. Ten of the eleven subjects had failed external beam radiation therapy prior to participating in the clinical trial. The results of this feasibility trial provided a basis for the pivotal study. Additional studies are still needed to satisfy the safety and effectiveness standards, including long term outcomes, set by the FDA for marketing approval.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate canc
'/>"/>

SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
4. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
7. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
8. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/11/2014)... July 11, 2014 Presently, disposable medical ... healthcare equipment and supplies segment. During the past two ... steady growth (on an average 12.5% per year), primarily ... settings. Currently, the US is the largest market for ... share of 40%. The second position is held by ...
(Date:7/11/2014)... -- Researchers from The Miriam Hospital have found ... have significantly higher rates of smoking than those ... were less likely to attempt quitting than those ... not be sufficient for this population. The study ... of print in the American Journal of ...
(Date:7/11/2014)... PULLMAN, Wash.The largest study of its kind has ... suite of advantages over their conventional counterparts, including ... , The study looked at an unprecedented 343 ... of organic and conventional plant-based foods, including fruits, ... meta-analysis techniques to quantify differences between organic and ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Delaying surgery to ... main ligament in the middle of the knee -- could ... They analyzed the medical records of 130 patients, aged ... patients, 62 had surgery less than six weeks after their ... the others had surgery more than three months after their ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- Prostate cancer patients are ... less effective treatment and die sooner if they also ... data from more than 41,200 American men who were ... They followed them through 2009. Nearly 1,900 of the ... years before their prostate cancer was discovered. "Men ...
Breaking Medicine News(10 mins):Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Depression May Make It Harder to Beat Prostate Cancer 2
... BOSTON--A surprise discovery -- that calorie-burning brown fat can be ... the prospect of new ways to fight obesity and overweight, ... Aug. 21 issue of the journal Nature, the ... "good" form of fat -- so called because it burns ...
... of new ways to treat obesity , , WEDNESDAY, Aug. ... also helps promote development of "good" brown fat that helps ... researchers at the Joslin Diabetes Center in Boston. , They ... lead to new ways to prevent and treat obesity. , ...
... Aug. 20 Digital health technologies designed to,monitor ... in U.S. revenues in,excess of $1.8 billion by ... in service and hardware,revenues, according to Parks Associates, ... medical, activity, and environmental,sensors and fitness measurement devices ...
... Aug. 20 Cord Blood America, Inc.,(OTC Bulletin ... preservation,company ( http://www.cordblood-america.com ) focused on bringing the ... and internationally,today reported that revenues for the first ... million., Revenues were down from the same ...
... fuels rapid growth by partnering with Flexicare Ltd., a ... intubation products]. , ... ... week that it had expanded its product offering of ...
... AggreWell™400 plate is a novel tool for standardizing the generation ... ... Vancouver, British Columbia (PRWEB) August 20, 2008 -- http://www.stemcell.com ... cell separation products and ancillary reagents for stem cell research, ...
Cached Medicine News:Health News:Making 'good' fat from muscle and vice versa 2Health News:Making 'good' fat from muscle and vice versa 3Health News:Bone Growth Protein Also Promotes 'Good' Fat 2Health News:Service and Hardware Revenues Will Contribute $1.8 Billion to the U.S. Eldercare Industry by 2013 2Health News:Cord Blood America Reports Six Month Financial Results 2Health News:ORSupply.com Introduces New Line of Products from Flexicare 2Health News:STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research 2
This is the modular VICTOR2 multilabel counter with the TR-fluorometry, stacker and robot loading options.The addition of a xenon flash lamp brings the time-resolved fluorescence counting mode to th...
Flexible and sensitive fluorescence/luminescence microplate reader for endpoint and kinetic...
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits....
... with a 25-microplate capacity ... and aspiration and dispense ... On-board software for user ... programs. External vacuum pump ...
Medicine Products: